Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT07393555)

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial): a one-minute explainerNCT073935551 min

Biospecimen Collection trial for Recurrent Lung Non-Small Cell Carcinoma (NCT07393555). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with stage IV or recurrent non-small-cell lung cancer and qualifying ALK, EGFR, ERBB2, MET, NTRK, RET or ROS1 alterations after targeted therapy and platinum chemotherapy. Prior PD-1/PD-L1 antibodies or TROP2-directed antibody-drug conjugates are excluded.

The idea: compare sacituzumab govitecan, ivonescimab or both. Sacituzumab delivers SN-38 to TROP2-bearing cells. Ivonescimab blocks PD-1 immune suppression and VEGF blood-vessel signaling. Infusions use three-week cycles. Researchers compare progression-free survival and responses. Entry requires progression after the latest systemic treatment.

This phase 2 study plans 117 patients. SWOG sponsors 41 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.